SANOFI INDIA LIMITED

Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846
Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2020

₹ in Million

Particulars	Quarter ended 31.03.2020 (Unaudited)	Quarter ended 31.12.2019 (Audited)	Quarter ended 31.03.2019 (Unaudited)	Year ended 31.12.2019 (Audited)
1. Revenue from Operations	7,845	8,263	7,173	30,706
2. Other Income	295	248	230	941
3. Total Income (1+2)	8,140	8,511	7,403	31,647
4. Expenses				
(a) Cost of Materials Consumed	2,422	2,301	2,127	8,636
(b) Purchases of stock in trade	1,187	1,227	1,330	4,815
(c) Changes in inventories of finished goods, stock in trade and work in progress	(207)	75	(378)	23
(d) Employee benefits expense	1,203	1,150	1,036	4,497
(e) Finance costs	5	3	-	3
(f) Depreciation and amortisation expense	207	215	261	999
(g) Other expenses	1,473	1,728	1,520	6,082
Total Expenses	6,290	6,699	5,896	25,055
5. Profit before exceptional item and tax (3-4)	1,850	1,812	1,507	6,592
6. Exceptional item (Refer note 4)	(504)	(199)	-	(593)
7. Profit before tax (5-6)	1,346	1,613	1,507	5,999
8. Tax expense				
Current Tax	535	724	590	2,276
Deferred Tax	(43)	(84)	(12)	(419)
9. Profit for the period (7-8)	854	973	929	4,142
10. Other comprehensive income (OCI) (Net of Tax)	(37)	(165)	-	(165)
11. Total comprehensive income for the period (9+10)	817	808	929	3,977
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230
13. Other equity	-	-	-	24,193
14. Basic and diluted earnings per share (not annualised)	37.08	42.26	40.34	179.85

RAJARAM NARAYANAN Digitally signed by RAJARAM NARAYANAN Date: 2020.05.19 12:33:58 +05'30'

ASHA RAMANATHAN Digitally signed by ASHA RAMANATHAN Date: 2020.05.19 13:20:39 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated May 19, 2020